RxDoctor Payments Data

Brian Perlmutter, MD

Interventional Cardiology · Sun City West, AZNPI 1851479380

Payments from drug & device makers

$6,115in general payments, 2019–2025

Across 233 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Abbott$706
  • Medtronic$585
  • Novartis$551
  • Abiomed$521
  • Edwards Lifesciences$429
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$6,02799%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,115 in reported general payments places this provider in the 30th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$758,948
Medicare patients
1,278
Services billed
9,629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban580$788,175
XareltoRivaroxaban86$121,524
BrilintaTicagrelor52$53,465
EntrestoSacubitril/Valsartan50$45,020
Repatha SureclickEvolocumab21$23,491
Metoprolol Succinate811$11,331
FarxigaDapagliflozin Propanediol13$7,475
Bumetanide230$5,656
Potassium Chloride339$5,323
Amiodarone Hcl252$5,062
Atorvastatin Calcium416$5,005
Rosuvastatin Calcium284$4,772
ClopidogrelClopidogrel Bisulfate321$4,398
SotalolSotalol Hcl118$3,573
Flecainide Acetate93$3,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$111$788,175580 claims
Johnson & JohnsonXarelto$86$121,52486 claims
AstraZenecaBrilinta, Farxiga$120$60,94065 claims
NovartisEntresto$551$45,02050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Sun City West

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →